Cocrystal Pharma’s (COCP) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Cocrystal Pharma (NASDAQ:COCP) in a research report released on Wednesday morning,Benzinga reports. The brokerage currently has a $7.00 price target on the stock. HC Wainwright also issued estimates for Cocrystal Pharma’s Q4 2024 earnings at ($0.47) EPS, FY2024 earnings at ($1.87) EPS, Q1 2025 earnings at ($0.54) EPS, Q2 2025 earnings at ($0.45) EPS, Q3 2025 earnings at ($0.31) EPS, Q4 2025 earnings at ($0.28) EPS and FY2025 earnings at ($1.50) EPS.

Cocrystal Pharma Trading Up 0.5 %

Shares of Cocrystal Pharma stock opened at $2.09 on Wednesday. The company has a fifty day moving average price of $2.16 and a 200 day moving average price of $1.99. Cocrystal Pharma has a twelve month low of $1.33 and a twelve month high of $3.26. The stock has a market cap of $21.26 million, a price-to-earnings ratio of -1.13 and a beta of 1.53.

Cocrystal Pharma Company Profile

Cocrystal Pharma, Inc, a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, norovirus, and respiratory virus infections.